The company said its dual sensor marks a world first, continuously measuring glucose and ketone levels every minute. Branded as Libre Duo and Libre Duo 10 Day, the sensors provide real-time visibility into glucose levels as a standard CGM like Abbott’s FreeStyle Libre system does, but also into rising ketones that can lead to a diabetic ketoacidosis (DKA) emergency.
Abbott said this clearance marks the first time people with diabetes can monitor ketones without traditional blood or urine tests. It plans to begin the rollout of its Libre Duo systems in select European countries later this year.
EVP of Diabetes Care Chris Scoggins explained the potential of the sensor in an interview with Drug Delivery Business News last year. Earlier this year, Abbott shared study data outlining the growing burden of DKA.
Get the full story at our sister site, Drug Delivery Business News.
